Stay updated with breaking news from Zhen Su. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A Novel TCR Vβ bifunctional selective T cell activator molecule for solid tumor treatmentMarengo to receive an associated milestone payment and eligible for additional future milestone payments, and tiered royalties
Phesi releases 2023 analysis of clinical development; breast cancer remains most studied disease area for third year
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the...
Karyopharm Therapeutics Inc. announced the appointment of Zhen Su, MD, MBA, to its Board of Directors, effective August 31, 2023. Dr. Su is currently Chief Executive Officer and a member of the Board...
Multi-year collaboration will sustain Ipsen’s presence in oncology by leveraging Marengo’s novel discovery of TCR Vβ-targeted precision T cell activation...